Telehealth triples genetic testing rates in childhood cancer survivors at elevated cancer risk

Adult survivors of childhood cancer carry elevated risks for a second, unrelated cancer - not a relapse of the original illness, but a new malignancy often years or decades later. Breast, colorectal, thyroid, and sarcoma cancers appear at higher rates in this population, largely because of the DNA-damaging effects of radiation and chemotherapy used during treatment. What is less commonly known is that a meaningful fraction of survivors - up to 13% - also carry hereditary gene variants that independently elevate their cancer risk, layering genetic predisposition on top of treatment-related susceptibility.

Knowing which survivors carry those variants allows oncologists to recommend earlier screening and preventive measures. But genetic counseling and testing have historically been poorly accessed by this population, partly because specialized genetic services are concentrated in major medical centers that may be far from where survivors live years after completing treatment.

A randomized trial published in Lancet Regional Health - Americas tested whether delivering genetic services remotely, through telehealth and in coordination with primary care providers, could change those rates.

The trial design and results

The study enrolled 391 adult survivors of childhood cancer with a mean age of 44 years. All participants received information about the potential benefits of genetic testing. Those randomized to the intervention arm received access to remote centralized telehealth genetic services, integrated with their primary care providers. The control group received usual care.

At six months, 43% of participants in the telehealth arm had completed genetic services, compared to 15% in the usual care group - a substantial difference in a population where genetic counseling access has typically been limited.

Among those who completed testing in the telehealth group, 10% had actionable results: hereditary variants that would change clinical management, typically by recommending earlier or more frequent cancer screenings or preventive interventions.

"Identifying survivors with cancer-predisposing genetic variants allows personalized survivorship care with early screenings and preventive measures," said lead author Tara Henderson, a childhood cancer survivorship expert and Chair of Pediatrics at Ann and Robert H. Lurie Children's Hospital of Chicago and Professor of Pediatrics at Northwestern University Feinberg School of Medicine. "Our study is the first national randomized trial to show that remote telehealth services, working with primary care providers, improve access to genetic counseling and testing for adult survivors of childhood cancers."

What 10% actionable results means

The 10% actionable finding is clinically significant. In a population of childhood cancer survivors where subsequent malignancy is already a known risk, identifying the subset with hereditary predisposition enables targeted surveillance that may detect second cancers earlier, when treatment is more likely to succeed. Henderson noted that genetic services "drive earlier detection of subsequent cancer, which reduces morbidity and mortality."

The hereditary variants with the largest consequences in this context are typically those associated with breast and ovarian cancer risk (BRCA1/2), Lynch syndrome (elevated colorectal and endometrial cancer risk), and Li-Fraumeni syndrome (elevated risk for multiple cancer types), though the specific distribution was not detailed in the available materials.

What still needs to improve

Even the improved 43% completion rate in the telehealth group means more than half of eligible survivors did not complete testing within six months. Henderson acknowledged this gap directly: "more survivors still need to pursue genetic testing. Enhancing motivation for testing may require personalized decision aids, further education about its benefits, and financial support mechanisms to reduce concerns about testing costs."

The trial's six-month follow-up window captures early uptake but may not reflect longer-term completion. Some survivors may pursue testing after the measurement window closed. The study also does not report on outcomes beyond test completion - whether actionable results translated into changed surveillance behavior and clinical outcomes will require longer-term follow-up data.

What the trial establishes clearly is that the delivery model matters. Integrating remote genetic services with primary care, rather than requiring survivors to independently navigate specialty genetics clinics, more than doubles the proportion who access this care. For a population that may have spent years trying to put cancer behind them, reducing barriers to genetic services has measurable effects on uptake.